Abstract
Inclusion of phenacetin among ‘proven’ human carcinogens by the IARC in 1987, raised concerns about the carcinogenic potential of acetaminophen, its major metabolite. Acetaminophen has been implicated as a possible causal agent in the development of cancer of the renal pelvis. The bladder and renal pelvis, which derive from the same embryological structure, share the same transitional type of epithelium. Past studies have been inconclusive on the possible relationship among these analgesics and bladder cancer but no large, highly detailed study of this association has been conducted. A population-based case–control study conducted in Los Angeles, California, involved 1514 incident bladder cancer cases and an equal number of controls who were matched to the index cases by sex, date of birth (within 5 years) and race. Detailed information on medication use and prior medical conditions was collected through in-person interviews. Regular use of analgesics was not associated with an increased risk of bladder cancer in either men or women. In fact, compared with non- or irregular users, regular analgesic users were at a decreased risk of bladder cancer overall (odds ratio (OR) = 0.81, 95% confidence interval (CI) = 0.68–0.96). However, there were clear differences in both the direction and strength of the associations between the different formulation classes of analgesics and bladder cancer risk. Intake of phenacetin was positively related to bladder cancer risk in a dose-dependent manner while intake of its major metabolite in humans, acetaminophen, was unrelated to risk. Intake of all classes of NSAIDs, except pyrazolon derivatives, were negatively associated with bladder cancer risk, with suggestive evidence that the protective effect varies in strength by subcategories of formulation. Acetic acids seemed to exhibit the strongest protective effect, whereas aspirin/other salicylic acids and oxicam showed the weakest protection. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Angervall L, Bengtsson U, Zetterlund CG and Zsigmond M (1969) Renal pelvic carcinoma in a Swedish district with abuse of a phenacetin-containing drug. Br J Urol 41: 401–405
Bernstein L and Ross RK (1991) Cancer in Los Angeles County. A Portrait of Incidence and Mortality 1972–1987. University of Southern California: Los Angeles, CA
Boring CC, Squires TS, Tong T and Montgomery S (1994) Cancer statistics, 1994. CA Cancer J Clin 44: 7–26
Breslow NE and Day NE (1980) Statistical Methods in Cancer Research, Vol. I: The Analysis of Case–Control Studies. IARC Scientific Publication 32. IARC: Lyon, France
Cohen SM, Hasegawa R, Sakata T and Johansson SL (1989) Effect of aspirin on urinary bladder carcinogenesis initiated with N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide in rats. Cancer Res 49: 372–377
Denda A, Endoh T, Kitayama W, Tang Q, Noguchi O, Kobayashi Y, Akai H, Okajima E, Tsujiuchi T, Tsutsumi M, Nakae D and Konishi Y (1997) Inhibition by piroxicam of oxidative DNA damage, liver cirrhosis and development of enzyme-altered nodules caused by a choline-deficient, L -amino acid-defined diet in rats. Carcinogenesis 18: 1921–1930
Derby LE and Jick H (1996) Acetaminophen and renal and bladder cancer. Epidemiology 7: 358–362
DuBois RN, Radhika A, Reddy BS and Entingh AJ (1996) Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 110: 1259–1262
Flaks B, Flaks A and Shaw AP (1985) Induction by paracetamol of bladder and liver tumours in the rat. Effects on hepatocyte fine structure. Acta Pathol Microbiol Immunol Scand [A] 93: 367–377
Fokkens W (1979) Phenacetin abuse related to bladder cancer. Environ Res 20: 192–198
Gago-Dominguez M, Yuan J-M, Castelao JE, Ross RK and Yu MC (1999) Regular use of analgesics is a risk factor for renal cell carcinoma. Br J Cancer 81: 542–548
Giardiello FM, Offerhaus GJ and DuBois RN (1995) The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Eur J Cancer 31A: 1071–1076
Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC and Speizer FE (1995) Aspirin and the risk of colorectal cancer in women. N Engl J Med 333: 609–614
Grubbs CJ, Juliana MM, Eto I, Casebolt T, Whitaker LM, Canfield GJ, Manczak M, Steele VE and Kelloff GJ (1993) Chemoprevention by indomethacin of N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced urinary bladder tumors. Anticancer Res 13: 33–36
Herschman HR (1994) Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. Cancer Metastasis Rev 13: 241–256
Hiraga K and Fujii T (1985) Carcinogenicity testing of acetaminophen in F344 rats. Jpn J Cancer Res 76: 79–85
Hultengren N, Lagergren C and Ljungqvist A (1965) Carcinoma of the renal pelvis in renal papillary necrosis. Acta Chir Scand 130: 314–320
Johansson S and Wahlqvist L (1977) Tumours of urinary bladder and ureter associated with abuse of phenacetin-containing analgesics. Acta Pathol Microbiol Scand [A] 85: 768–774
Johansson SL (1981) Carcinogenicity of analgesics: long-term treatment of Sprague-Dawley rats with phenacetin, phenazone, caffeine and paracetamol (acetaminophen). Int J Cancer 27: 521–529
Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA and Jothy S (1995) Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 55: 2556–2559
Kari F, Bucher J, Haseman J, Eustis S and Huff J (1995) Long-term exposure to the anti-inflammatory agent phenylbutazone induces kidney tumors in rats and liver tumors in mice. Jpn J Cancer Res 86: 252–263
Kelloff GJ, Boone CW, Crowell JA, Steele VE, Lubet R and Sigman CC (1994) Chemopreventive drug development: perspectives and progress. Cancer Epidemiol Biomarkers Prev 3: 85–98
Klän R, Knispel HH and Meier T (1993) Acetylsalicylic acid inhibition of N-butyl-(4-hydroxybutyl) nitrosamine-induced bladder carcinogenesis in rats. J Cancer Res Clin Oncol 119: 482–485
Kokmen E, Beard CM, O'Brien PC, Offord KP and Kurland LT (1993) Is the incidence of dementing illness changing? A 25-year time trend study in Rochester, Minnesota (1960–1984). Neurology 43: 1887–1892
Kosary CL, Ries LAG, Miller BA, Hankey BF, Harras A and Edwards BK (eds) (1995) SEER Cancer Statistics Review, 1973–1992: Tables and Graphs, National Cancer Institute. NIH Pub. No. 96-2789, Bethesda, MD
Kune GA, Kune S and Watson LF (1988) Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res 48: 4399–4404
Liu L, Deapen D, Berstein L and Ross R (1998) Cancer in Los Angeles County: Incidence and Mortality by Race/Ethnicity 1988–1995. Los Angeles County Cancer Surveillance Program, University of Southern California,
Liu XH and Rose DP (1996) Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res 56: 5125–5127
Lupulescu A (1996) Prostaglandins, their inhibitors and cancer. Prostaglandins Leukot Essent Fatty Acids 54: 83–94
McCredie M and Stewart JH (1988) Does paracetamol cause urothelial cancer or renal papillary necrosis? Nephron 49: 296–300
McCredie M, Ford JM, Taylor JS and Stewart JH (1982) Analgesics and cancer of the renal pelvis in New South Wales. Cancer 49: 2617–2625
McCredie M, Stewart JH, Ford JM and MacLennan RA (1983) Phenacetin-containing analgesics and cancer of the bladder or renal pelvis in women. Br J Urol 55: 220–224
McGeer PL, Schulzer M and McGeer EG (1996) Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology 47: 425–432
Marnett LJ (1992) Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 52: 5575–5589
Moon RC, Detrisac CJ, Thomas CF and Kelloff GJ (1992) Chemoprevention of experimental bladder cancer. J Cell Biochem Suppl 161: 134–138
Moon RC, Kelloff GJ, Detrisac CJ, Steele VE, Thomas CF and Sigman CC (1993) Chemoprevention of OH-BBN-induced bladder cancer in mice by piroxicam. Carcinogenesis 14: 1487–1489
Müller-Decker K, Scholz K, Marks F and Fürstenberger G (1995) Differential expression of prostaglandin H synthase isozymes during multistage carcinogenesis in mouse epidermis. Mol Carcinog 12: 31–41
Murai T, Mori S, Machino S, Hosono M, Takeuchi Y, Ohara T, Makino S, Takeda R, Hayashi Y and Iwata H (1993) Induction of renal pelvic carcinoma by phenacetin in hydronephrosis-bearing rats of the SD/cShi strain. Cancer Res 53: 4218–4223
Murasaki G, Zenser TV, Davis BB and Cohen SM (1984) Inhibition by aspirin of N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide-induced bladder carcinogenesis and enhancement of forestomach carcinogenesis. Carcinogenesis 5: 53–55
National Center for Health Statistics (1996) Vital Statistics of the United States, 1992: Vol. 2, Mortality, Part A United States Department of Health and Human Services Publication PHS 96–1101. US Dept of Health and Human Services, Public Health Service, CDC: Hyattsville MD
Okajima E, Denda A, Ozono S, Takahama M, Akai H, Sasaki Y, Kitayama W, Wakabayashi K and Konishi Y (1998) Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N -butyl- N -(4-hydroxybutyl) nitrosamine. Cancer Res 58: 3028–3031
O'Neill GP, Mancini JA, Kargman S, Yergey J, Kwan MY, Falgueyret JP, Abramovitz M, Kennedy BP, Ouellet M and Cromlish W (1994) Overexpression of human prostaglandin G/H synthase-1 and -2 by recombinant vaccinia virus: inhibition by nonsteroidal anti-inflammatory drugs and biosynthesis of 15-hydroxyeicosatetraenoic acid. Mol Pharmacol 45: 245–254
Piper JM, Tonascia J and Matanoski GM (1985) Heavy phenacetin use and bladder cancer in women aged 20 to 49 years. N Engl J Med 313: 292–295
Rao KV, Detrisac CJ, Steele VE, Hawk ET, Kelloff GJ and McCormick DL (1996) Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis 17: 1435–1438
Ristimäki A, Honkanen N, Jänkälä H, Sipponen P and Härkönen M (1997) Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res 57: 1276–1280
Shibata MA, Hasegawa R, Shirai T, Takesada Y and Fukushima S (1993) Chemoprevention by indomethacin of tumor promotion in a rat urinary bladder carcinogenesis model. Int J Cancer 55: 1011–1017
Steering Committee of the Physicians' Health Study Research Group (1989) Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 321: 129–135
Thun MJ, Namboodiri MM, Calle EE, Flanders WD and Heath CW Jr (1993) Aspirin use and risk of fatal cancer. Cancer Res 53: 1322–1327
Yu MC and Ross RK (1998) Epidemiology of bladder cancer, Carcinoma of the Bladder. Innovations in ManagementPetrovich Z, Baert L and Brady LW (eds), pp.1–13, Springer Verlag: Berlin, Heidelberg
Yu MC, Yuan JM and Ross RK (1999) Epidemiology of renal cell carcinoma. Carcinoma of the Kidney, Testis and Rare Urologic Malignancies: Innovations in Management, Petrovich Z, Baert L and Brady LW (eds), pp.3–13. Springer Verlag: Berlin, Heidelberg
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Castelao, J., Yuan, JM., Gago-Dominguez, M. et al. Non-steroidal anti-inflammatory drugs and bladder cancer prevention. Br J Cancer 82, 1364–1369 (2000). https://doi.org/10.1054/bjoc.1999.1106
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.1106
Keywords
This article is cited by
-
Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies
BMC Cancer (2018)
-
Expression pattern of p53-binding protein 1 as a new molecular indicator of genomic instability in bladder urothelial carcinoma
Scientific Reports (2018)
-
Neutrophil-to-lymphocyte ratio is a prognostic marker in bladder cancer patients after radical cystectomy
BMC Cancer (2016)
-
Spray Dried Chitosan Microparticles for Intravesical Delivery of Celecoxib: Preparation and Characterization
Pharmaceutical Research (2016)
-
Can daily intake of aspirin and/or statins influence the behavior of non-muscle invasive bladder cancer? A retrospective study on a cohort of patients undergoing transurethral bladder resection
BMC Cancer (2015)